We provide professional support in Neurovision.
AmbP iNet application is used as a supplement to the
personalized occlusion treatment for lazy eye in children aged 4-9 years.
Recent research supported by the US National Institutes
of Health/National Eye Institute reaffirms that occlusion and/or eye drops may
be the correct course of treatment. These new studies suggest closure
during visual activities. Thus, hand-eye coordination will be encouraged
in the child with amblyopia, which will generally improve visual acuity.
This vision therapy program, which has been designed to
help both forcing the amblyopic eye to “see well” and to provide more
advanced hand-eye coordination, strengthens the development of vision by
attracting attention with the various activities it includes.
The program will start at the level to be determined by
your eye doctor. Your correct and incorrect reactions and the improvement
in your vision will be evaluated automatically by the program.
As your or your child’s vision improves, the program will
automatically switch to a more challenging level. Thus, it is ensured that
the patient’s performance and the difficulty of the therapy are determined.
Your doctor will inform you which eye will be closed
during the treatment. The treatment is applied 5 days a week, for 30
minutes. It is recommended that you study five days a week until the next
examination, when your doctor will let you know when you can stop.
MAKE SURE THE DISTANCE BETWEEN YOUR CHILD AND THE SCREEN IS 40 CM . Moving
closer to the screen makes the targets appear larger and hinders the
achievement of the work done.
RevitalVision by NeuroVision™ is a technology that
provides an increase in visual acuity and contrast acuity by teaching vision
directly to the brain through studies using computers and personalized programs
in the treatment of adult amblyopia (lazy eye) between the ages of 9- 55.
The visual stimulations in this application directly
stimulate the visual center in the brain and as a result, “Contrast
Sensitivity, Visual Acuity and Quality” increase. It is a
“non-invasive” (non-invasive, non-surgical) vision enhancement
treatment based on visual stimulation and accelerating the neural connections
responsible for vision.
The technology has been clinically proven to treat adult
amblyopia (lazy eye), which until now was considered incurable. It has FDA
approval and Medical CE-Mark permission.
Best corrected Visual Acuity (BCVA) is expected to
increase by 2 ETDRS orders or more.
Contrast sensitivity is expected to rise to the level of normal limits.
Amblyopia patients may also experience improvement in their binocular functions.